Brooks Lab board approves demerger of Manufacturing Business into Abridge

Demerger ratio announcedStrategic Transactions View source PDF Explain this filing

BROOKS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.1%Reaction day

₹68.73

prior close

₹69.15

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+3.8% vs market

On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.0

10m

+1.8

15m

+2.5

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+2.1-1.6+3.8

Next day

-2.5-1.0-1.6

-4.6-2.6-2.0

-12.7-5.1-7.6

-12.0-6.1-5.9

-15.2-8.3-6.9

-13.5-6.4-7.1

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Brooks Lab board approved a Scheme of Arrangement to demerge its Manufacturing Business (Baddi facility) into wholly owned subsidiary Abridge Speciality. The demerged unit contributed about 96.66% of FY26 turnover (Rs. 8,287.26 lakhs). Share ratio is 1:1, no cash consideration. Resulting company will seek listing on BSE and NSE. Upon effectiveness, Abridge will be renamed Brooks Laboratories and the existing entity becomes Xuri Lifesciences. Subject to SEBI, NCLT and shareholder approvals. Listing expected in about 16 months.

Likely market impact

Shareholders get 1 new Abridge share per Brooks Lab share held, plus existing shares. Both entities to list, subject to regulatory approvals.